ALS Researchers Uncover New Insights into Motor Neuron Death

According to Brian Kaspar, MD, a principal investigator in the Center for Gene Therapy at Nationwide Children’s and senior author of the new study, inhibiting NF-kB in microglia decreased ALS progression by 47 percent. “

ImStar Selects Lead ALS Drug Candidate for Study by Mid-2014

“We are very excited to announce the selection of IMS-088 as ImStar’s lead ALS compound. As we continue with preclinical development next year, we hope to establish IMS-088 as a safe and effective new drug candidate for ALS,” said Jean-Pierre Julien, ImStar’s chief scientific officer.

Neuraltus’ NP001 Phase 2 Results Highlighted at 24th International Symposium on ALS/MND

According to a post hoc analysis, a greater percentage of patients receiving NP001 experienced a halt in disease progression which reached statistical significance when compared to the combination of concurrent and matched historical (placebo) controls. The high dose of NP001 (2mg/kg) halted progression in 27% of patients compared to 11% of patients on placebo. Further, NP001 was found to be safe and well-tolerated in the study.

ALS TDI and Neurimmune Partner to Advance Treatments for ALS

The ALS Therapy Development Institute (ALS TDI), together with its wholly-owned subsidiary, Anelixis Therapeutics, announced today that it has formed a research partnership with Neurimmune to advance potential treatments for ALS, also known as Lou Gehrig’s disease.

University of Adelaide Sheds Light on Neurodegenerative Pathway

University of Adelaide researchers have identified a likely molecular pathway that causes a group of untreatable neurodegenerative diseases, including Huntington’s disease and Lou Gehrig’s disease.
The group of about 20 diseases, which show overlapping symptoms that typically include nerve cell death, share a similar genetic mutation mechanism ? but how this form of mutation causes these [...]

RASCALS Board of Directors Welcomes Sandra Putney as New Treasurer

The Robert A. Stehlin Campaign for ALS (R.A.S.C.A.L.S.) is delighted to welcome Sandra Putney to the foundation’s Board of Directors, where she will assume the duties of Treasurer. Sandra is committed to using her business acumen and leadership abilities to safeguard donor dollars while ensuring that donations are maximized for the organization’s mission.

RASCALS Salutes Greg Reagan

The R.A.S.C.A.L.S. would like to acknowledge Greg Regan, who stepped down earlier this year from his post as Treasurer for the foundation. A member of the organization’s inaugural Board of Directors, Greg was instrumental in helping lay the groundwork for this charity’s signature events and educational efforts.

Thank You For Helping Us Take Another Step Forward in the Fight Against ALS

My heartfelt thanks goes out to all of you who helped to make the R.A.S.C.A.L.S. Second Annual 5K Walk/Run a resounding success.

2013 RASCALS 5K Official Results

2013 RASCALS 5K Official Results by Age Group and Overall Rankings.

Acceleration of Clinical Program in ALS Confirms Proof of Efficacy Data Obtained in Animals

AB Science SA, a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces, following the press release from November 4, that the acceleration of the clinical development program in ALS is in line with proof of efficacy experiments conducted in two different models that generated positive results of increased survival.